Please use this identifier to cite or link to this item: https://ninho.inca.gov.br/jspui/handle/123456789/7750
Title: Impact of Symptomatic Metastatic Spinal Cord Compression on Survival of Patients with Non-Small-Cell Lung Cancer
Authors: Silva, Gustavo Telles da
Bergmann, Anke
Thuler, Luiz Claudio Santos
Keywords: Estudos de Coortes
Cohort Studies
Coluna Vertebral
Spine
Compressão da Medula Espinal
Spinal Cord Compression
Metástase Neoplásica
Neoplasm Metastasis
Carcinoma Pulmonar de Células não Pequenas
Carcinoma Non-Small-Cell Lung
Sobrevida
Survival
Issue Date: 2017
Publisher: World Neurosurg
Citation: SILVA, Gustavo Telles da; BERGMANN, Anke; THULER, Luiz Claudio Santos. Impact of Symptomatic Metastatic Spinal Cord Compression on Survival of Patients with Non-Small-Cell Lung Cancer. World Neurosurg, v. 168, p. 698-704, dec. 2017.
Abstract: Non-small-cell lung cancer (NSCLC) is one of the most common primary tumor sites among patients with metastatic spinal cord compression (MSCC). This disorder is related to neurologic dysfunction and can reduce the quality of life, but the association between MSCC and death is unclear. The aim of this study was to analyze the impact of the occurrence of symptomatic MSCC on overall survival of patients with NSCLC. - METHODS: A cohort study was carried out involving 1112 patients with NSCLC who were enrolled between 2006 and 2014 in a single cancer center. Clinical and socio demographic data were extracted from the physical and electronic records. Survival analysis of patients with NSCLC was conducted using the Kaplan-Meier method. A log-rank test was used to assess differences between survival curves. Cox proportional hazards regression ana lyses were carried out to quantify the relationship between the independent variable (MSCC) and the outcome (overall survival). - RESULTS: During the study period, the incidence of MSCC was 4.1%. Patients who presented with MSCC were 1.43 times more likely to die than were those with no history of MSCC (hazard ratio, 1.43; 95% confidence interval [CI], 1.03e2.00; P [ 0.031). The median survival time was 8.04 months (95% CI, 6.13e9.96) for those who presented MSCC and 11.95 months (95% CI, 10.80e13.11) for those who did not presented MSCC during the course of disease (P [ 0.002). CONCLUSIONS: MSCC is an important and independent predictor of NSCLC worse survival. This effect was not influenced by sociodemographic and clinical factors.
Description: p. 698-704.: tab. p&b.
URI: http://sr-vmlxaph03:8080/jspui/handle/123456789/7750
ISSN: 1878-8769
Appears in Collections:Artigos de Periódicos da área de Fisioterapia



Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.